Adenosine deaminases that act on RNA (ADARs) have been reported to be functional on various viruses. ADAR1 may exhibit antiviral or proviral activity depending on the type of virus. Human immunodeficiency virus (HIV)-1 is the most well-studied lentivirus with respect to its interaction with ADAR1, and variable results have been reported. In this study, we demonstrated that equine ADAR1 (eADAR1) was a positive regulator of equine infectious anemia virus (EIAV), another lentivirus of the Retroviridae family. First, eADAR1 significantly promoted EIAV replication, and the enhancement of viral protein expression was associated with the long terminal repeat (LTR) and Rev response element (RRE) regions. Second, the RNA binding domain 1 of eADAR1 was essential only for enhancing LTR-mediated gene expression. Third, in contrast with APOBEC proteins, which have been shown to reduce lentiviral infectivity, eADAR1 increased the EIAV infectivity. This study indicated that eADAR1 was proviral rather than antiviral for EIAV.
Introduction
Adenosine deaminases that act on RNA (ADARs) are RNAediting enzymes that recognize double stranded RNA (dsRNA) and mediate the conversion of adenosine (A) to inosine (I) (Bass, 2002; Nishikura, 2010; Samuel, 2011) . The base-pairing properties of inosine are different from those of adenosine, and thus, A-to-I editing alters RNA structure, coding potential and splicing patterns (Samuel, 2011) . Recently, ADARs have been shown to edit the genomes of many viruses, including the measles virus (Cattaneo et al., 1988) , human parainfluenza virus (Murphy et al., 1991) , respiratory syncytial virus (Martinez et al., 1997) , influenza virus (Gutierrez et al., 2013; Suspene et al., 2011) , lymphocytic choriomeningitis virus (Zahn et al., 2007) , human T-cell leukemia virus type 2 and simian T-cell leukemia virus type 3 (Ko et al., 2012) , during viral infection. Notably, ADAR1 can either promote or inhibit viral replication. For certain viruses, such as human immunodeficiency virus (HIV)-1, vesicular stomatitis virus (VSV) and hepatitis D virus (HDV) (Casey, 2006; Clerzius et al., 2009; Doria et al., 2011; Nie et al., 2007; Phuphuakrat et al., 2008) , ADAR1 is proviral. However, ADAR1 inhibits the replication of other viruses, such as hepatitis C virus (Taylor et al., 2005) and the measles virus (Ward et al., 2011) . For HIV-1 and VSV, ADAR1 enhances viral replication by inhibition of dsRNA activated protein kinase (PKR), which suppresses viruses replication by shutting off the expression of viral proteins (Clerzius et al., 2009; Gelinas et al., 2011; Li et al., 2010; Nie et al., 2007) . HDV replication requires ADAR1 editing activity for producing its large antigen by catalyzing stop codon UAG into tryptophan codon UGG in HDV mRNA (Casey, 2006) . However, in general, virus replication inhibition was suspected due to ADAR1 massive editing activity (Ko et al., 2012; Suspene et al., 2011; Taylor et al., 2005) .
Similar to HIV-1, equine infectious anemia virus (EIAV) is a member of the Lentivirus genus of the Retroviridae family. EIAV causes a persistent infection characterized by recurring febrile episodes associated with viremia, fever, thrombocytopenia and wasting symptoms in equids (Leroux et al., 2004) . However, with respect to HIV-1 studies, different results have been found regarding the interaction of ADAR1 and HIV-1. Many groups have found that ADAR1 positively regulates HIV-1 (Clerzius et al., 2009; Doria et al., 2011; Phuphuakrat et al., 2008) , and one group has reported that ADAR1 inhibits HIV-1 replication (Biswas et al., 2012) . Consequently, investigating the interaction between EIAV and ADAR1 will increase our understanding of the ADAR1 function in lentiviruses.
Results

Equine ADAR1 positively regulated EIAV, HIV-1 and SIV replication
To investigate the role of eADAR1 in EIAV replication, HEK293T cells were co-transfected with the eADAR1 expression plasmid and EIAV-CMV-3-8, an EIAV proviral clone derived from the live attenuated vaccine strain EIAV FDDV13 (Tang et al., 2014; Wang et al., 2011) . The amounts of EIAV-CMV-3-8 in the cell lysates and culture supernatants were estimated by measuring the levels of EIAV Gag (p55) and capsid (CA or p26, cleaved from p55) protein by western blot at 48 h post transfection (hpt). As shown in Fig. 1A , the levels of the viral capsid protein and its precursor in the cell lysate were significantly greater in cells co-transfected with ADAR1, and this increase was dose dependent. Furthermore, the levels of p26 in viral particles released into the culture supernatant also increased substantially in response to ADAR1 overexpression.
These results indicate that EIAV production increased in response to eADAR1 overexpression. To determine whether eADAR1 promotes the replication of viruses other than EIAV, we examined the effects of eADAR1 overexpression on human lentivirus HIV-1 and simian lentivirus simian immunodeficiency virus (SIV) replication. HEK293T cells were co-transfected with the plasmids expressing either HIV-1 NL4-3 or SIV mac239 , together with increasing doses of the eADAR1 expression vector. The levels of viral Gag protein in the cell lysates and culture supernatants were examined by western blot. As shown in Fig. 1B and C, the amounts of both HIV-1 and SIV structural proteins in both cell lysates and supernatants increased with increasing levels of eADAR1 expression, indicating that eADAR1 activity upregulates the replication of multiple lentiviral species.
To examine whether endogenous eADAR1 also promotes EIAV replication, we targeted ADAR1 in eMDMs with specific siRNAs, resulting in efficient knockdown of ADAR1 expression at the mRNA level (Fig. 1D) . Twelve hours post siRNA transfection, 2.5 ng of EIAV DLV34 (as determined by RT activity) was used to infect the cells in 96-well plates. Viruses were collected from the supernatant and titrated by measuring the viral RT activity 72 h post infection (hpi). Our results show that the knockdown of eADAR1 significantly inhibited the production of EIAV (Fig. 1E ) compared with the mock and non-specific siRNA controls.
Equine ADAR-1-mediated promotion of EIAV expression is associated with the LTR and RRE regions ADAR1 binding on RNA depends on the double-stranded RNA secondary structure (Bass, 2002; Nishikura, 2010; Samuel, 2011) . It is logical to investigate whether this structure is also essential for the activity of ADAR1 in promoting EIAV expression. In the single-stranded positive-sense RNA genome of EIAV, two regions contain such secondary structures: the long terminal repeat (LTR) and the Rev response element (RRE) regions in the envelope (env) gene. We first investigated whether the LTR region is necessary for eADAR1-mediated promotion of EIAV expression. The EIAV LTR region functions as the promoter for EIAV transcription. We subcloned this fragment into a pGL3-Basic plasmid to measure the activity of LTR by detecting downstream luciferase activity. To determine whether eADAR1 affects EIAV LTR-mediated gene expression, fetal equine dermal (FED) cells were co-transfected with the LTR-luciferase plasmid and either the eADAR1 expression plasmid or an empty vector. The results, presented in Fig. 2A , showed that eADAR1 overexpression increased luciferase activity by a factor of 4.22 compared with the vector control, indicating that eADAR1 expression enhances LTR-mediated gene expression. The result indicated that the eADAR1-mediated increase in luciferase expression correlated with the LTR region.
Next, we examined the role of the RRE region in eADAR1-promoting activity. We constructed two different expression plasmids for EIAV env expression that expressed either the wildtype env (pEIAV-Env) with a functional RRE region or a codonoptimized env (pEIAV-Env-opti), in which the RRE secondary structure was destroyed. HEK293T cells were then transfected with one of these plasmids and the ADAR1 expression vector. The level of viral envelope protein (Env) expressed in these cells was examined by western blot. As presented in Fig. 2B and C, eADAR1 overexpression increased the Env expression in cells expressing the wild-type env gene, but not in cells expressing the env gene that lacked the RRE secondary structure. This finding indicates that an intact RRE secondary structure is required for eADAR1-mediated promotion of Env expression.
We also investigated the effects of ADAR1 on two nonstructural EIAV proteins: transactivator of transcription (Tat) and regulator of virion expression (Rev), which regulate viral replication (Dorn and Derse, 1988; Leroux et al., 2004; Martarano et al., 1994) . EIAV Tat or Rev was expressed in HEK293T cells, together with increasing doses of eADAR1. The levels of Tat and Rev protein in cell lysates were examined by western blot. We did not observe any noticeable changes in the densities of the relevant bands ( Fig. 2D and E), indicating that eADAR1 overexpression did not affect the expression of these regulatory proteins. The Tat coding region does not encode a double-stranded RNA secondary structure, and Rev contains only a partial RRE sequence . Our results further confirm that an intact RRE is essential for eADAR1 to promote viral protein expression.
The eADAR1 RNA binding domain 1 was required to promote EIAV expression
When compared with the sequence of human ADAR1, eADAR1 was predicted to consist of three functional regions. The Nterminal region contains two copies of a Z-DNA binding domain, Zα and Zβ. The central region of eADAR1 contains a doublestranded RNA-binding domain, designated as dsRBD or R. The C-terminal region of eADAR1 is the deaminase catalytic domain (Cat). As shown in Fig. 1A and 2A, eADAR1 enhanced EIAV protein expression and was associated with the LTR region. To determine which domain or domains of eADAR1 were required to promote EIAV gene expression, we generated constructs in which the DNA binding domain, the RNA binding domain or the Cat domain of eADAR1 was deleted (Fig. 3A) . We then examined the ability of these deletion mutants to promote LTR-mediated gene expression by co-transfecting plasmids expressing the eADAR1 deletion mutants and the LTR-luciferase reporter plasmid into FED cells and measuring the resulting luciferase activity. Western blot analysis showed that these eADAR1 mutants were expressed at the predicted molecular weights (Fig. 3B ). As shown in Fig. 3C , deletion of the RNA-binding domain, but not the DNA-binding domain or Cat domain, significantly decreased the luciferase activity, indicating that RNA binding was required for ADAR1 upregulation of EIAV protein expression.
We further examined the roles of these three domains separately with respect to the activity of a LTR-luciferase reporter ( Fig. 3D and E) . Only the RNA-binding region was sufficient to positively regulate LTR-luciferase expression (Fig. 3F) . Because the RNA-binding region contains three RNA-binding domains (RI, RII and RIII), each of these domains was further either deleted or expressed separately to investigate its role in enhancing LTRluciferase expression (Fig. 4A, B and D, E) . To our surprise, deleting RI alone eliminated the enhancement of LTR-luciferase activity by eADAR1 (Fig. 4C) , and expression of only RI was sufficient to enhance the LTR activity to an extent similar to that observed with intact eADAR1 (Figs. 4F and 3F ). These results indicate that the RI domain is essential for the eADAR1-mediated promotion of LTR- Virus production was quantified by western blotting using an anti-EIAV p26 monoclonal antibody. EIAV p26 enhanced by eADAR1 was quantified by densitometry scanning of western blot images of three independent experiments. *Po 0.05. (B) Overexpression of eADAR1 increased HIV-1 production. HEK293T cells were transfected with 500 ng of HIV-1 NL4-3 proviral DNA along with different amounts of the eADAR1 expression vector (0, 0.5, 1 or 2 μg). The levels of HIV-1 NL4-3 and eADAR1 expression were detected by western blot. HIV-1 p24 expression enhanced by ADAR1 was quantified by densitometry scanning of western blot images of three independent experiments. *Po 0.05. (C) Overexpression of eADAR1 increased SIV production. HEK293T cells were transfected with 500 ng of SIV mac239 proviral DNA along with different amounts of the ADAR1 expression vector (0, 0.5, 1 or 2 μg). The levels of SIV mac239 and eADAR1 expression were detected by western blot. SIV p27 expression enhanced by ADAR1 was quantified by densitometry scanning of western blot images of three independent experiments. *P o0.05. (D) eADAR1 transcription was knocked down by siRNA. eMDMs were transfected with either 50 nM of one of three ADAR1-specific siRNA species (siADAR1 1-3) or 50 nM of a scrambled siRNA control (siScr) or mock transfected (Mock). At 24 hpt, eADAR1 (upper panel) and β-actin (lower panel) mRNA levels were quantified by semi-quantitative PCR. (E) Knockdown of eADAR1 transcription increased EIAV replication in equine monocyte-derived macrophages (eMDMs). eMDMs were transfected with 50 nM siADAR1 or siScr for 12 h and then infected with 2.5 ng of EIAV DLV34 . The viral titers in the supernatants were assessed at 72 hpi by measuring the RT activity. P values o0.05 were considered statistically significant. The images shown in A, B and C are representative of three independent experiments. *P o0.05, from three independent experiments. mediated gene expression. This characteristic differs from human ADAR for HIV-1, for which integrity of the three RNA binding domains is necessary for HIV-1 LTR activation (Clerzius et al., 2009 ).
Overexpression of equine ADAR1 increased EIAV infectivity
The APOBEC3 family of cytidine deaminases plays an important role in restricting retroviruses by introducing G-to-A hypermutation effect of this equine adenosine deaminase on EIAV infectivity. We prepared two one-life cycle EIAV-luciferase reporter viruses using HEK293T cells co-transfected with a plasmid expressing either eADAR1 (ADAR1) or donkey APOBEC A3Z3 (doA3Z3), a donkey homolog of human APOBEC3s that restricts EIAV infectivity (unpublished data). These two pseudoviruses, EIAV-ADAR1 and EIAV- doA3Z3, were used to infect HEK293T cells at identical doses, which were standardized using a reverse transcriptase (RT) activity assay (Fig. 5B) . Intracellular luciferase activity was quantified at 24 hpi. As shown in Fig. 5A , EIAV-doA3Z3 was poorly infectious, whereas EIAV-ADAR1 was highly infectious, suggesting that ADAR1 plays a different role in viral infections than the APOBEC3 proteins.
Discussion
The ability of this adenosine deaminase to promote EIAV replication can be explained by the following eADAR1 activities. First, the eADAR1 promotion of EIAV replication is dependent on RNA binding activity (Figs. 3 and 4) . This property may be result from ADAR1 binding to PKR, which inhibits PKR kinase activity, resulting in reduced eIF-2a phosphorylation and protein synthesis (Clerzius et al., 2009 Pfaller et al., 2011) . Indeed, our results show that the eADAR1-mediated promotion of EIAV gene expression is associated with the LTR and RRE regions (Fig. 2) , which have been reported to contain RNA secondary structures. The secondary structure is necessary for PKR activation Cole, 2007; Sadler and Williams, 2007) . However, further studies are necessary to determine whether the eADAR1 stimulation of EIAV expression is mediated by the binding of ADAR1 to RNA secondary structures or by other editing-independent pathways, for instance, through competitive inhibition of RNA binding to toll-like receptors (TLRs) and retinoic acid inducible-gene I (RIG-I), which are innate sensors of foreign RNAs and induce antiviral responses (Wu and Chen, 2014) . Second, eADAR1 induces an A-to-G mutation, which facilitates the adaptation of the virus to a new host. Unlike the G-to-A hypermutation induced by APOBEC3 proteins (Lecossier et al., 2003; Mangeat et al., 2003; Zhang et al., 2003) , the A-to-G mutation does not generate stop codons that cause the premature termination of protein translation. Additionally, in contrast with APOBEC3G, which is packaged into virions and induces G-to-A mutations in the genomes of viral progeny, ADAR1 introduces A-to-G mutations to the genomes of viral progeny, and these mutations improve viral replication in the next replication cycle. Thus, ADAR1 enhances the ability of a virus to infect a host.
ADAR1 has been identified as a positive regulator of HIV-1 in several studies (Clerzius et al., 2009; Doria et al., 2011; Phuphuakrat et al., 2008) . However, a recent publication reported that ADAR1 inhibits HIV-1 replication (Biswas et al., 2012) . It is unclear why these studies obtained contrary results. These inconsistencies may result from ADAR1 editing activities. Indeed, ADAR1 has dual roles in virus replication. If ADAR1 edits viral genomes to an appropriate extent, viral replication is favored. In contrast, when ADAR1 edits viral genomes massively, virus replication can be hindered. In the present study, we showed that eADAR1 did not massively edit EIAV genomes (unpublished data), which may be one of the mechanisms by which eADAR1 enhances EIAV replication.
In conclusion, we demonstrated that eADAR1 positively regulates EIAV replication, as evidenced by its ability to enhance LTR-mediated gene expression, EIAV capsid expression and infectivity. However, further investigation is necessary to determine whether additional genomic mutations are required to enhance eADAR1-induced virus production.
Materials and methods
Plasmids
Equine ADAR1 (eADAR1) cDNA was cloned from mRNA extracted from eMDMs and expressed using the adenoviral expression vector pDC315 (Microbix Biosystems, Canada) to generate a protein fused to an HA tag at the C-terminus (pADAR1). A set of expression vectors with deletion mutations in the eADAR1 cDNA were constructed using the primers listed in Table S1 . All of the constructed mutants were confirmed by sequencing. The plasmid pEIAV-Env expressing the codon-optimized EIAV envelope gene (env) was derived from the EIAV strain EIAV FDDV 3-8 (FDDV3-8) and was kindly provided by Dr. YiMing Shao (Meng et al., 2011) . EIAV-CMV-3-8 is an infectious EIAV clone derived from FDDV3-8 by substituting the U3 region of the 5 0 LTR with the CMV promoter . The HIV-1 NL4-3 and SIVmac239 infectious clones were generously provided by Dr. YongHui Zheng. The EIAV Tat fragment was amplified from FDDV3-8 and subcloned into the pEGFP-N1 mammalian expression vector (Clontech, USA) with an HA tag (Tang et al., 2014) . The expression plasmids for the EIAV non-optimized envelope protein (Env) and the nonstructural protein Rev were constructed as described previously (Yin et al., 2014) .
Cells and virus stocks
Primary eMDMs were prepared from equine peripheral blood mononuclear cells (PBMCs) as described previously and maintained in RPMI 1640 medium containing 60% fetal bovine serum (FBS). HEK293T and HEK293 cells were maintained in Dulbecco's Modified Eagle's Medium containing 10% FBS. A donkey MDM (dMDM)-adapted pathogenic EIAV strain, EIAV DLV34 (DLV34), was titrated using a reverse transcriptase (RT) assay kit (Roche, Switzerland) according to the manufacturer's instructions.
EIAV infectivity assay using a luciferase-expressing reporter virus HEK293T cells were co-transfected with 3.5 μg of either pADAR1 or donkey APOBEC A3Z3 and 1.5 μg of pONY8.1-LUC, 1.5 μg pEIAV- together with DNA from a three-plasmid lentivirus package system (1.5 μg of pONY8.1-LUC transfer plasmid, 1.5 μg of pEIAV-GagPol packaging plasmid and 0.5 μg of pMD2.0G envelope plasmid), using the calcium phosphate method. The resulting pseudoviruses were collected and quantified by measuring the viral RT activity. HEK293T cells were infected with identical doses of EIAV. Luciferase activity was detected at 24 hpi. (B) eADAR1 was not packaged into EIAV virions. The pseudovirus in the supernatant of transfected HEK293T cells was collected, and the virion quantities were adjusted based on RT activity before being examined by western blot. An EIA-positive serum was used to detect EIAV p26, and an HA antibody was used to detect the HA tag fused to eADAR1 and donkey A3Z3. Data were collected from three independent experiments. The image shown is from a representative experiment. *P o0.05.
GagPol and 0.5 μg of pMD2.0 G, using the calcium phosphate method (Tang et al., 2014; Yin et al., 2014) . The VSV-G-packaged pseudovirus was collected 48 hpt and used to infect HEK293T cells seeded in 48-well plates. These cells were washed and subjected to luciferase analysis at 24 hpi.
siRNA knockdown of eADAR1 mRNA in eMDMs Three ADAR1-specific siRNAs (siADAR 1-3; see Table S1 for the sequences) and a scrambled siRNA negative control (siScr) were synthesized by RiboBio, China. Equine MDMs were seeded in 96-well plates and cultivated for three days. The cells were then washed twice with PBS before being transfected with either eADAR1-specific or negative control siRNA (diluted to 50 nM in serum-free media). Knockdown of eADAR1 mRNA was verified by reverse transcription PCR.
Transfections and western blotting
Cells were transiently transfected with the plasmids described above using Lipofectamine 2000 (Invitrogen, USA) according to the manufacturer's instructions. At 48 hpt, the cells and culture supernatants were collected separately. The cells were washed once with PBS and then lysed in RIPA Lysis Buffer containing a protease inhibitor cocktail (Roche, Switzerland). The supernatants were centrifuged at 12,000g for 10 min at 4 1C to remove cell debris and centrifuged again at 20,000g for 2 h at 4 1C to precipitate the EIAV particles. The proteins in the cell lysates and supernatant precipitates were separated by SDS-PAGE, transferred to PVDF membranes (Millipore, Germany) and probed with antibodies.
